We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
LONDON--Oxford Biomedica PLC (OXB.LN) said Thursday it has signed a three-year agreement with Novartis AG (NOVN.EB) for the commercial and clinical supply of lentiviral vectors, a deal that could bring $100 million to Oxford over the next three years.
The gene and cell therapy group said the agreement can be extended to five years.
Lentiviral vectors are a type of retrovirus that can infect both dividing and nondividing cells because their preintegration complex can get through the intact membrane of the nucleus of the target cell.
Chief Executive John Dawson said: "The new deal with Novartis will strengthen the group's balance sheet immediately and will support the group's continued growth over the next three years."
Shares at 0725 GMT down 0.1 pence, or 1%, at 9.75 pence.
-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
July 06, 2017 03:47 ET (07:47 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
